Quality Assured Services (QAS) is a direct marketer of point-of-care and self-testing diagnostic products. It distributes easy-to-use diagnostic kits directly to consumers' homes, as well as to health professionals and home health care providers. Its products include anticoagulation tests, cholesterol tests, and other products that monitor and diagnose such conditions as blood pressure, diabetes, lung function, and infectious diseases. The company also provides telemedicine support, patient management software, insurance verification, and billing services. QAS is a subsidiary of diagnostic products firm Inverness Medical Innovations.

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on the areas of serious unmet medical need, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer's disease. Its lead products include cardiovascular medicines, including PLAVIX and AVAPRO/AVALIDE; ABILIFY, a medicine for the treatment of mental illness; ERBITUX, SPRYCEL, and IXEMPRA, which are cancer medicines; HIV medicines, such as REYATAZ, SUSTIVA, and ATRIPLA; BARACLUDE, a medicine for hepatitis B; ONGLYZA, a type 2 diabetes treatment; and ORENCIA, a medicine for rheumatoid arthritis. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, dapagliflozin, ipilimumab, belatacept, and brivanib. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer, Inc.; and various biotech companies.

AVIVA Biosciences develops biochips to speed drug discovery and research. The chips help researchers learn how cells interact with each and their environment which in turn helps scientists to create drugs that target those behaviors. The firm is also developing a means for isolating hard-to-detect rare cells from blood samples; this technology could be used in prenatal care, such as detecting Down syndrome in the first trimester of pregnancy. It can also be used for cancer diagnostics. Chinese life sciences company, CapitalBio, is AVIVA's primary shareholder.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

Biodel Inc. company was founded in 2003 and is headquartered in Danbury, Connecticut. Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. The company develops its product candidates by utilizing its proprietary VIAdel technology that allows to study the interaction between peptide hormones and small molecules. Its product candidates include VIAject, an injectable formulation of recombinant human insulin, which has completed two pivotal Phase III clinical trials for the treatment of Type 1 and Type 2 diabetes; and VIAtab, a sublingual tablet formulation of insulin, which has completed Phase I clinical trial for Type 1 diabetes.

Eli Lilly and Company was founded in 1876 and is based in Indianapolis, Indiana. Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. It offers neuroscience products to treat schizophrenia, manic episodes, and bipolar maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; depression, bulimia nervosa, and obsessive-compulsive disorders; and bipolar depression. The company's endocrinology products are used for diabetes; type 2 diabetes; osteoporosis in postmenopausal women; osteoporosis in postmenopausal women and men at high risk for fracture; and human growth hormone deficiency and idiopathic short stature.Eli Lilly and Company also provides oncology products to prevent pancreatic, metastatic breast, non-small cell lung, ovarian, and bladder cancers; malignant pleural mesothelioma; and colorectal cancers, as well as offers cardiovascular products for treating erectile dysfunction, atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention and adults with severe sepsis at high risk of death. In addition, the company offers animal health products, such as cattle feed additives; antibiotics used to treat respiratory diseases and other diseases in cattle, swine, and poultry; protein supplements to improve milk productivity in dairy cows; anticoccidial agents for use in poultry; antibiotics used to control enteric infections in calves and swine; parasiticides for use on cattle and premises; and products that prevents flea infestations on dogs, as well as other pharmaceutical products to treat staphylococcal infections and bacterial infections. Eli Lilly distributes its products principally through independent wholesale distributors, as well as directly to pharmacies. It has a strategic alliance with MacroGenics, Inc.; and licensing and development agreements with TransPharma Medical Ltd. and BioMS Medical Corp.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and Racivir for the treatment of human immunodeficiency virus (HIV) infection. The company has three product candidates under development, which include RG7128, a HCV nucleoside polymerase inhibitor that is in Phase IIb clinical trial; PSI-7851, a HCV nucleotide polymerase inhibitor that completed Phase I clinical trial; and Racivir, which completed Phase II clinical trial, for the treatment of HIV. It has strategic collaboration agreement with F. Hoffmann-LaRoche Ltd. and Hoffmann-La Roche Inc. for the development of PSI-6130 and its products, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; Emory University; Bukwang Pharm. Co., Ltd; University of Georgia Research Foundation, Inc. and Yale University; and Boehringer Ingelheim Chemicals, Inc.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.